Of Mice and Man: The Unwinding of CLEC-2 as an Antithrombotic Target?

James D. McFadyen; Pierre H. Mangin; Karlheinz Peter

doi:10.1055/a-1938-1380

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2022; 122(12): 1963-1965
DOI: 10.1055/a-1938-1380

Invited Editorial Focus

Of Mice and Man: The Unwinding of CLEC-2 as an Antithrombotic Target?

James D. McFadyen

¹Atherothrombosis and Vascular Biology Program, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia

²Department of Haematology, Alfred Hospital, Melbourne, Victoria, Australia

³Department of Cardiometabolic Health, The University of Melbourne, Parkville, Victoria, Australia

,

Pierre H. Mangin^*

⁴INSERM, EFS Grand-Est, BPPS UMR-S1255, FMTS, Université de Strasbourg, Strasbourg, France

,

Karlheinz Peter^*

¹Atherothrombosis and Vascular Biology Program, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia

³Department of Cardiometabolic Health, The University of Melbourne, Parkville, Victoria, Australia

⁵Department of Cardiology, Alfred Hospital, Melbourne, Victoria, Australia

References
1 McFadyen JD, Stevens H, Peter K. The emerging threat of (micro)thrombosis in COVID-19 and its therapeutic implications. Circ Res 2020; 127 (04) 571-587
2 Stevens H, Canovas R, Tran H, Peter K, McFadyen JD. Inherited thrombophilias are associated with a higher risk of COVID-19-associated venous thromboembolism: a prospective population-based cohort study. Circulation 2022; 145 (12) 940-942
3 Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood 2019; 133 (09) 906-918
4 Ziegler M, Wang X, Peter K. Platelets in cardiac ischaemia/reperfusion injury: a promising therapeutic target. Cardiovasc Res 2019; 115 (07) 1178-1188
5 McFadyen JD, Kaplan ZS. Platelets are not just for clots. Transfus Med Rev 2015; 29 (02) 110-119
6 Gaertner F, Massberg S. Patrolling the vascular borders: platelets in immunity to infection and cancer. Nat Rev Immunol 2019; 19 (12) 747-760
7 Rayes J, Watson SP, Nieswandt B. Functional significance of the platelet immune receptors GPVI and CLEC-2. J Clin Invest 2019; 129 (01) 12-23
8 Arman M, Krauel K. Human platelet IgG Fc receptor FcγRIIA in immunity and thrombosis. J Thromb Haemost 2015; 13 (06) 893-908
9 Boulaftali Y, Hess PR, Getz TM. et al. Platelet ITAM signaling is critical for vascular integrity in inflammation. J Clin Invest 2013; 123 (02) 908-916
10 Bénézech C, Nayar S, Finney BA. et al. CLEC-2 is required for development and maintenance of lymph nodes. Blood 2014; 123 (20) 3200-3207
11 Herzog BH, Fu J, Wilson SJ. et al. Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2. Nature 2013; 502 (7469): 105-109
12 Lowe KL, Finney BA, Deppermann C. et al. Podoplanin and CLEC-2 drive cerebrovascular patterning and integrity during development. Blood 2015; 125 (24) 3769-3777
13 Rayes J, Jadoui S, Lax S. et al. The contribution of platelet glycoprotein receptors to inflammatory bleeding prevention is stimulus and organ dependent. Haematologica 2018; 103 (06) e256-e258
14 Haining EJ, Lowe KL, Wichaiyo S. et al. Lymphatic blood filling in CLEC-2-deficient mouse models. Platelets 2021; 32 (03) 352-367
15 Hitchcock JR, Cook CN, Bobat S. et al. Inflammation drives thrombosis after Salmonella infection via CLEC-2 on platelets. J Clin Invest 2015; 125 (12) 4429-4446
16 Payne H, Ponomaryov T, Watson SP, Brill A. Mice with a deficiency in CLEC-2 are protected against deep vein thrombosis. Blood 2017; 129 (14) 2013-2020
17 Rayes J, Lax S, Wichaiyo S. et al. The podoplanin-CLEC-2 axis inhibits inflammation in sepsis. Nat Commun 2017; 8 (01) 2239
18 May F, Hagedorn I, Pleines I. et al. CLEC-2 is an essential platelet-activating receptor in hemostasis and thrombosis. Blood 2009; 114 (16) 3464-3472
19 Suzuki-Inoue K, Fuller GL, García A. et al. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood 2006; 107 (02) 542-549
20 Morán LA, Di Y, Sowa MA. et al. Katacine is a new ligand of CLEC-2 that acts as a platelet agonist. Thromb Haemost 2022; 122 (08) 1361-1368
21 Haining EJ, Cherpokova D, Wolf K. et al. CLEC-2 contributes to hemostasis independently of classical hemITAM signaling in mice. Blood 2017; 130 (20) 2224-2228
22 Shao B, Hoover C, Shi H. et al. Deletion of platelet CLEC-2 decreases GPIbα-mediated integrin αIIbβ3 activation and decreases thrombosis in TTP. Blood 2022; 139 (16) 2523-2533
23 Gitz E, Pollitt AY, Gitz-Francois JJ. et al. CLEC-2 expression is maintained on activated platelets and on platelet microparticles. Blood 2014; 124 (14) 2262-2270
24 Bourne J, Smith C, Jooss N. et al. CLEC-2 supports platelet aggregation in mouse but not human blood at arterial shear. Thromb Haemost 2022; 122 (12) 1988-2000
25 McFadyen JD, Schaff M, Peter K. Current and future antiplatelet therapies: emphasis on preserving haemostasis. Nat Rev Cardiol 2018; 15 (03) 181-191
26 Rowley JW, Oler AJ, Tolley ND. et al. Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes. Blood 2011; 118 (14) e101-e111
27 Lee M, Saver JL, Hong K-S, Wu H-C, Ovbiagele B. Risk of intracranial hemorrhage with protease-activated receptor-1 antagonists. Stroke 2012; 43 (12) 3189-3195
28 Mangin PH, Neeves KB, Lam WA. et al; Subcommittee on Biorheology. In vitro flow-based assay: from simple toward more sophisticated models for mimicking hemostasis and thrombosis. J Thromb Haemost 2021; 19 (02) 582-587